WHO issues its first global guideline on GLP-1 medicines for obesity

The World Health Organization today published its first global guideline on the use of glucagon-like peptide-1 (GLP-1) medicines for the treatment of obesity in adults, formally placing a drug class that has reshaped obesity care in high-income countries onto the agenda of health ministries that mostly cannot afford it [s1].

The guideline covers three medicines — liraglutide, semaglutide and tirzepatide — and issues two recommendations. Both are conditional [s1].

What "conditional" means here

In WHO's grading system, a conditional recommendation is not an endorsement of universal adoption. It signals that the balance of benefits and harms is close enough, or the surrounding evidence uncertain enough, that the right decision depends on context. WHO attributes the conditional grading to limited long-term safety data, cost, and equity implications [s1].

The first recommendation is that adults living with obesity may receive GLP-1 therapies as long-term treatment. Pregnant women are excluded [s1]. The second recommendation is that intensive behavioural interventions combining a healthy diet and physical activity may accompany a GLP-1 prescription; WHO notes this recommendation rests on low-certainty evidence [s1].

That second point is worth pausing on. The guideline is explicit that medication alone is not a solution to obesity, and calls for comprehensive approaches spanning population-level policy, targeted screening, and lifelong person-centred care [s1]. But the evidence base for bolting intensive lifestyle programmes onto drug therapy is graded low-certainty — which is an honest admission that the combination most clinicians would consider obvious has not been well studied.

The numbers WHO is working from

WHO frames obesity as a chronic, relapsing disease. More than one billion people worldwide are affected, and 3.7 million deaths were attributed to obesity in 2024 [s1]. Without action, WHO projects the number of cases will roughly double by 2030, with a predicted annual economic cost of US$3 trillion by that year [s1].

Against that, the access projection: fewer than 10% of people who could benefit are projected to be able to obtain GLP-1 therapies by 2030 [s1].

That single figure is the reason this guideline reads less like a clinical document and more like a market-shaping one. A recommendation that reaches under a tenth of its intended population is not, in practice, a treatment policy.

The pricing paragraph is the point

The guideline pairs its clinical recommendations with an unusually direct warning on equity. WHO states that without deliberate policies, access to these therapies could exacerbate existing health disparities [s1]. The strategies it names are the standard levers of the access-to-medicines toolkit: pooled procurement, tiered pricing, and voluntary licensing [s1].

None of these is available to WHO to impose. They are recommendations to governments and, by implication, to the manufacturers who hold the patents. What WHO can supply is normative cover — a document that a health ministry can point to when it argues that obesity medicines belong in the same conversation as HIV antiretrovirals or hepatitis C cures, categories where pooled procurement and licensing eventually did move prices.

Whether that analogy holds is unsettled. Antiretrovirals and direct-acting antivirals were curative or life-sustaining in populations with acute mortality. GLP-1 therapies, on WHO's own framing, are long-term treatment for a chronic relapsing condition — meaning the cost is not a course but an annuity, borne for as long as the patient remains on therapy.

What the guideline does not settle

Several things are conspicuously outside the document's scope as announced. The recommendation covers adults; it does not extend to children or adolescents [s1]. It excludes pregnant women [s1]. And WHO's stated reason for conditional grading includes limited long-term safety data [s1] — an acknowledgement that the durability question, for a therapy explicitly framed as lifelong, is not yet answered by the trial record.

The guideline also does not resolve what happens when treatment stops. WHO's framing of obesity as "chronic, relapsing" and its definition of long-term treatment as continuous therapy of at least six months point at the problem without claiming to have solved it.

What to watch

Three things. First, whether any large-volume purchaser — Gavi, the Global Fund, a regional procurement pool, or a national ministry — actually attempts pooled procurement on the strength of this guideline, and what price emerges. Second, whether voluntary licensing materialises for any of the three named molecules. Third, whether WHO follows this adult guideline with separate guidance on adolescents, where the clinical and ethical questions are sharper and the evidence thinner.

Nothing in this guideline tells an individual reader what to take. It is a document addressed to health systems, and its central claim is that the systems most affected by obesity are the least equipped to pay for the drugs now being recommended.

Sources

• [s1] World Health Organization, "WHO issues global guideline on the use of GLP-1 medicines in treating obesity," 1 December 2025. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity